Table 2.
Current Clinical Trials*
| Phase | Name | Target Disease | NCT# |
|---|---|---|---|
| I | Blinatumomab | Non-Hodgkin’s Lymphoma | NCT00274742 |
| I | MT111/MEDI-565 | Gastrointestinal Adenocarcinomas | NCT01284231 |
| I | BAY2010122 | Prostatic neoplasms | NCT01723475 |
| I | MT110 | Solid tumors | NCT00635596 |
| I | Blinatumomab | B-cell and Non-Hodgkin’s Lymphoma | NCT00538096 |
| I/II | Blinatumomab | Acute Lymphoblastic Leukemia (child and adolescent) | NCT01471782 |
| I/II | Blinatumomab | Chronic lymphocytic Leukemia | NCT00676871 |
| II | Blinatumomab | Acute Lymphoblastic Leukemia | NCT00560794 |
| II | Blinatumomab | Diffuse Large B-cell Lymphoma | NCT01741792 |
| II | Blinatumomab | Acute Lymphoblastic Leukemia | NCT01466179 |
| II | Blinatumomab | Philadelphia Chromosome Negative and Positive Adult Precursor Acute Lymphoblastic Leukemia | NCT02143414 |
| II | Blinatumomab | Acute Lymphoblastic Leukemia | NCT01207388 |
| II | Blinatumomab | B-ALL | NCT01209286 |
| II | Blinatumomab | Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia | NCT02000427 |
| III | Blinatumomab | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | NCT02013167 |
| III | Blinatumomab | B-cell Adult Acute Lymphoblastic Leukemia; Philadelphia Chromosome-Negative Adult Precursor Acute Lymphoblastic Leukemia | NCT02003222 |
| III | Blinatumomab | B-cell Adult Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia | NCT02101853 |
| Blinatumomab | Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia | NCT02187354 |
*
Listing accurate as of July 31, 2014.